Trial Profile
A Phase 1, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-1287 to Patients With Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs TP 1287 (Primary)
- Indications Advanced breast cancer; Bladder cancer; Ewing's sarcoma; Liposarcoma; Malignant melanoma; Medulloblastoma; Neuroblastoma; Prostate cancer; Renal cell carcinoma; Sarcoma; Small cell lung cancer; Solid tumours; Synovial sarcoma
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Sumitomo Pharma America; Sumitomo Pharma Oncology
- 08 Mar 2024 Status changed from recruiting to discontinued.
- 06 Jun 2023 Phase 1 dose-escalation in solid tumors has completed and TP-1287 is being investigated in a dose expansion cohort in patients with Ewing sarcoma
- 06 Jun 2023 Trial design of the expansion part, presented at the 59th Annual Meeting of the American Society of Clinical Oncology